MedTrace Logo

Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

NCT00277069 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2010-01-07

No results posted yet for this study

Summary

1\. Determine the response rate with this regimen in an anthracycline and taxane resistant cohort of patients.

Conditions

Interventions

DRUG

Carboplatin

Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days

DEVICE

Capecitabine

Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days

DRUG

Vinorelbine

Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days

Sponsors & Collaborators

  • University of New Mexico

    lead OTHER

Principal Investigators

  • Ian Rabinowitz, MD · University of New Mexico

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Primary Completion
2005-03-31
Completion
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00277069 on ClinicalTrials.gov